Valuation
- Market cap
- 3,813,000
- Revenue TTM
- $0
- Net income TTM
- $-19,420,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- 0.00%
- Debt to equity
- 0.00
Trading
- Volume
- 11,532
- Avg volume
- 215,126
- Day's range
- $0.35 – $0.40
- Shares out
- 10,736,000
- Stochastic %K
- 25%
- Beta
- 0.68
- Analysts
- Strong Buy
- Price target
- —
Company profile
PharmaCyte Biotech, Inc., a biotechnology company, focused on developing and preparing to commercialize cellular therapies for cancer using live cell encapsulation technology in the United States. The company's cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer. It also develops CypCaps for pancr...
Show more
PharmaCyte Biotech, Inc., a biotechnology company, focused on developing and preparing to commercialize cellular therapies for cancer using live cell encapsulation technology in the United States. The company's cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer. It also develops CypCaps for pancreatic cancer and other solid cancerous tumors. It has a cooperation agreement with Iroquois Master Fund Ltd.; license agreements with SG Austria Pte. Ltd.; and Austrianova Singapore Pte. Ltd. to use the Cell-in-the-Box technology for cancer treatment. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was incorporated in 1996 and is headquartered in Las Vegas, Nevada.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 917 595 2850
- Website
- https://pharmacyte.com
- Address
- 3960 Howard Hughes Parkway, Suite 500, Las Vegas, United States
Latest news
No headlines yet.
